AstraZeneca Net Income 2010-2024 | AZN

AstraZeneca annual/quarterly net income history and growth rate from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • AstraZeneca net income for the quarter ending June 30, 2024 was $1.927B, a 6% increase year-over-year.
  • AstraZeneca net income for the twelve months ending June 30, 2024 was $6.440B, a 4.48% increase year-over-year.
  • AstraZeneca annual net income for 2023 was $5.955B, a 81.11% increase from 2022.
  • AstraZeneca annual net income for 2022 was $3.288B, a 2835.71% increase from 2021.
  • AstraZeneca annual net income for 2021 was $0.112B, a 96.5% decline from 2020.
AstraZeneca Annual Net Income
(Millions of US $)
2023 $5,955
2022 $3,288
2021 $112
2020 $3,196
2019 $1,335
2018 $2,155
2017 $3,001
2016 $3,499
2015 $2,825
2014 $1,233
2013 $2,556
2012 $6,240
2011 $9,917
2010 $8,053
2009 $7,544
AstraZeneca Quarterly Net Income
(Millions of US $)
2024-06-30 $1,927
2024-03-31 $2,180
2023-12-31 $959
2023-09-30 $1,374
2023-06-30 $1,818
2023-03-31 $1,804
2022-12-31 $902
2022-09-30 $1,640
2022-06-30 $360
2022-03-31 $386
2021-12-31 $-347
2021-09-30 $-1,652
2021-06-30 $550
2021-03-31 $1,561
2020-12-31 $1,012
2020-09-30 $648
2020-06-30 $756
2020-03-31 $780
2019-12-31 $313
2019-09-30 $299
2019-06-30 $130
2019-03-31 $593
2018-12-31 $1,034
2018-09-30 $431
2018-06-30 $350
2018-03-31 $340
2017-12-31 $1,301
2017-09-30 $686
2017-06-30 $477
2017-03-31 $537
2016-12-31 $1,842
2016-09-30 $1,014
2016-06-30 $-3
2016-03-31 $646
2015-12-31 $808
2015-09-30 $770
2015-06-30 $697
2015-03-31 $550
2014-12-31 $-321
2014-09-30 $254
2014-06-30 $796
2014-03-31 $504
2013-12-31 $-524
2013-09-30 $1,246
2013-06-30 $823
2013-03-31 $1,011
2012-12-31 $1,507
2012-09-30 $1,511
2012-06-30 $1,597
2012-03-31 $1,625
2011-12-31 $1,493
2011-09-30 $3,477
2011-06-30 $2,113
2011-03-31 $2,907
2010-12-31 $1,632
2010-09-30 $1,554
2010-06-30 $2,116
2010-03-31 $2,777
2009-12-31 $1,562
2009-09-30 $2,115
2009-06-30 $1,707
2009-03-31 $2,144
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $221.444B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69